Concert Pharmaceuticals (Concert Pharmaceuticals) Cash-to-Debt : 10.52 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Concert Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2022 was 10.52.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Concert Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

The historical rank and industry rank for Concert Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

CNCE' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.34 Med: 9.82 Max: No Debt
Current: 10.52

During the past 11 years, Concert Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 1.34. And the median was 9.82.

CNCE's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.54 vs CNCE: 10.52

Concert Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Concert Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Concert Pharmaceuticals Cash-to-Debt Chart

Concert Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

6.88

8.25

9.50

Concert Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash-to-Debt	Get a 7-Day Free Trial															6.94	9.50	7.43	10.66	10.52

Competitive Comparison of Concert Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Concert Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concert Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's Cash-to-Debt falls into.

Concert Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Concert Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	143.099	/	(1.155	+	13.91)
	=	9.50

Concert Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	149.533	/	(1.345	+	12.868)
	=	10.52

Concert Pharmaceuticals (NAS:CNCE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Concert Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421

Website

https://www.concertpharma.com

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Executives

James V Cassella	officer: Chief Development Officer	2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker	officer: CFO, PFO	175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart	officer: Chief Operating Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie	officer: Chief Legal Officer	CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung	director, officer: Chief Executive Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt	director
Thomas G Auchincloss	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich	director	1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland	director	C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett	director	C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511